RayKnowChina Research Map
Shortlist

YantaiQingdao University

Yantai Yuhuangding Hospital

烟台毓璜顶医院

Listed for 24 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Yantai Yuhuangding Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌3 papers led
  2. Hepatocellular carcinoma肝细胞癌12 papers led
  3. Stomach cancer胃癌33 papers led
  4. Lung cancer肺癌47 papers led1 open trial led
  5. Pancreatic cancer胰腺癌7 papers led
  6. Breast cancer乳腺癌45 papers led1 open trial led
  7. Retinoblastoma视网膜母细胞瘤2 papers led
  8. Osteosarcoma骨肉瘤3 papers led
  9. Gastrointestinal stromal tumour胃肠道间质瘤2 papers led
  10. Neuroblastoma神经母细胞瘤1 paper led
  11. Aplastic anaemia再生障碍性贫血1 paper led
  12. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症1 paper led
  13. Lymphoma淋巴瘤12 papers led
  14. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  15. Coronary heart disease冠心病10 papers led
  16. Congenital heart disease先天性心脏病2 papers led
  17. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎0 papers led
  18. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  19. Fabry disease法布雷病0 papers led
  20. Behçet disease白塞病1 paper led
  21. Alport syndromeAlport 综合征1 paper led
  22. IgA nephropathyIgA 肾病0 papers led
  23. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
  24. Hereditary angioedema遗传性血管性水肿1 paper led

Not listed for: Oesophageal squamous cell carcinoma, Glioma, Hepatoblastoma, Chordoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Scoliosis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Pompe disease, Duchenne muscular dystrophy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 3 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Yantai for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRadiotherapy techniqueRecurrent / metastatic disease
Departments in papersENT / head & neck surgeryRadiation oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 12 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.08%.

Papers led
12
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 2220232024: 5520242025: 112025

1 hospital in Yantai for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesLocal treatment (ablation, TACE, HAIC)Imaging, AI & early detectionImmunotherapy & targeted drugs
Departments in papersMedical oncologySurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineGastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led12
  1. Construction of a prognostic model and identification of key genes in liver hepatocellular carcinoma based on multi-omics data.2025Scientific reportsFree full text
  2. Diagnostic efficacy of contrast-enhanced ultrasound, dynamic contrast-enhanced MRI combined with tumor markers AFP and DCP for primary hepatocellular carcinoma.2024Biotechnology & genetic engineering reviews
  3. hsa_circ_0072309 Inhibits Oncogenesis in Hepatocellular Carcinoma by Epigenetic Activation of its Host Gene.2024Cell biochemistry and biophysics
  4. Meta-Analysis on the Therapeutic Effect of Transcatheter Arterial Chemoembolization Combined with Portal Vein Embolization.2024Chemotherapy
  5. Sarcopenia as a prognostic factor in patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus sorafenib.2024Journal of cancer research and therapeutics
  6. Cost-Effectiveness Analysis of Hepatic Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in China: A Comparative Analysis of HAIC-FO and Sorafenib.2024Medical science monitor : international medical journal of experimental and clinical researchFree full text
  7. In vivo study revealed pro-tumorigenic effect of CMTM3 in hepatocellular carcinoma involving the regulation of peroxisome proliferator-activated receptor gamma (PPARγ).2023Cellular oncology (Dordrecht, Netherlands)Free full text
  8. Construction of pain prediction model for patients undergoing hepatic arterial chemoembolization.2023World journal of surgical oncologyFree full text
  9. Circ_0005397 enhances hepatocellular carcinoma progression through miR-1283/HEG1.2022Annals of hepatology
  10. LINC00536 promotes hepatocellular carcinoma progression via the miR-203b-5p/VEGFA axis.2022Neoplasma
  11. Cell division cycle associated 2 (CDCA2) upregulation promotes the progression of hepatocellular carcinoma in a p53-dependant manner.2022PeerJFree full text
  12. Long non-coding RNA 01559 mediates the malignant phenotypes of hepatocellular carcinoma cells through targeting miR-511.2021Clinics and research in hepatology and gastroenterology
All its trials on ClinicalTrials.gov, any status2
  1. Predictive Model for Pain After TACECompletedNCT05545046Lead sponsorStart 2019-09
  2. TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular CarcinomaStatus unknownNCT01605734Study sitePhase 2Start 2012-07

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 33 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
33
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 7720212022: 6620222023: 6620232024: 5520242025: 992025

1 hospital in Yantai for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    TEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)
    Phase
    N/A
    Started
    2026-07
    Posted
    Registry
    NCT07714980

    Age 18 years to 80 years (registered criteria)

    Led by Affiliated Hospital of Qingdao University; 5 listed hospitals as study sitesBeijing, Qingdao, Weifang, Weihai, Yantai

  2. Recruiting
    First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06730373

    Age 18 years to 75 years (registered criteria)

    Led by Qilu Hospital of Shandong University; 7 listed hospitals as study sitesJinan, Linyi, Qingdao, Yantai, Zhengzhou, Zibo

  3. Recruiting
    TEAS for Gastrectomy Recovery
    Phase
    N/A
    Started
    2024-10
    Posted
    Registry
    NCT07898293

    Age 18 years to 80 years (registered criteria)

    Led by Affiliated Hospital of Qingdao University; 2 listed hospitals as study sitesQingdao, Weifang, Yantai

  4. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Posted
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapy & targeted drugsImaging & AISurgery
Departments in papersMedical oncologyGastroenterology / hepatologyPathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)
Papers it led33
  1. Prognostic and immunological implications of protein kinases in gastric cancer: a focus on hub gene ABL2 and its impact on the polarization of M2 macrophages.2025Biology directFree full text
  2. LRRC25 Is a Potential Biomarker for Predicting Immunotherapy Response in Patients with Gastric Cancer.2025Digestive diseases and sciencesFree full text
  3. Real-World Efficacy of Cadonilimab Plus Chemotherapy as Second-Line Therapy in Immunotherapy-Pretreated Advanced HER2 Negative Gastric or Gastroesophageal Junction Cancer.2025Drug design, development and therapyFree full text
  4. Efficacy and safety of immunotherapy rechallenge in second-line treatment after failure of first-line immune checkpoint inhibitors combined with chemotherapy in advanced gastric cancer: a retrospective study.2025Frontiers in immunologyFree full text
  5. Efficacy and safety of sintilimab combined with trastuzumab and chemotherapy in HER2-positive advanced gastric or gastroesophageal junction cancer.2025Frontiers in immunologyFree full text
  6. Exploring Metabolomic Drivers of Colorectal and Gastric Cancer: A Mendelian Randomisation Study.2025Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  7. Macrophages in tertiary lymphoid structures promote apoptosis of ATF4-positive gastric cancer cells via IL18.2025Journal of translational medicineFree full text
  8. High glycemic variability serves as an independent risk factor for postoperative infection-related complications in patients undergoing radical surgery for gastric, colon, and rectal cancer.2025MedicineFree full text
  9. Cancer-associated fibroblast subtype and risk signature as predictors of prognosis and treatment effectiveness in gastric cancer.2025Scientific reportsFree full text
  10. Effect of Intensive Nursing Management on Quality of Life and Mental Health in Elderly Gastric Cancer Patients Undergoing Chemotherapy: A Retrospective Study.2024British journal of hospital medicine (London, England : 2005)
  11. Case report: Significant response of alpha-fetoprotein-producing gastric cancer from combined chemotherapy and immunotherapy.2024Frontiers in immunologyFree full text
  12. IGFL2 expression and surgical volume: Independent predictors of survival in gastric cancer.2024MedicineFree full text
  13. A disulfidptosis-related classification and risk signature identifies immunotherapy biomarkers and predicts prognosis in gastric cancer: An observational study.2024MedicineFree full text
  14. Construction and validation of a TTN mutation associated immune prognostic model for evaluating immune microenvironment and outcomes of gastric cancer: An observational study.2024MedicineFree full text
  15. Clinical characteristics and survival outcomes in patients with primary ovarian carcinoid: A historical cohort study.2023Acta obstetricia et gynecologica ScandinavicaFree full text
  16. Gastric cystica profunda with upper GI bleeding.2023Asian journal of surgery
  17. LncRNA SNHG22 promotes gastric cancer progression by regulating the miR-101-3p/e2f2 axis.2023Cell cycle (Georgetown, Tex.)Free full text
  18. Circ-0000979 promotes the development of gastric carcinoma by sponging miR-136 and modulating SP1 mRNA expression level.2023Histology and histopathology
  19. TAF15 promotes cell proliferation, migration and invasion of gastric cancer via activation of the RAF1/MEK/ERK signalling pathway.2023Scientific reportsFree full text
  20. SAMD4A serves as a negative prognostic marker for gastric cancer patients.2023Tissue & cell
  21. A new way of laparoscopic spleen-preserving splenic hilar lymphadenectomy for the treatment of upper gastric cancer.2022Asian journal of surgery
  22. LINC01857 promotes the proliferation, migration, and invasion of gastric cancer cells via regulating miR-4731-5p/HOXC6.2022Canadian journal of physiology and pharmacology
  23. Linc-ROR promotes invasion and metastasis of gastric cancer by activating epithelial-mesenchymal transition.2022Indian journal of pathology & microbiology
  24. Application of clinical nursing pathway in nursing care of patients undergoing gastric cancer surgery.2022Minerva gastroenterology
  25. Efficacy of the Short-Term versus Long-Term Administration of Antimicrobial Prophylaxis in Gastric Cancer Surgery: A Meta-Analysis of Randomized Controlled Trials.2022Surgical infections
  26. Complete remission of alpha-fetoprotein-producing gastric cancer by combined tislelizumab-apatinib treatment of a patient with proficient mismatch repair: a case report.2022World journal of surgical oncologyFree full text
  27. EPLIN Expression in Gastric Cancer and Impact on Prognosis and Chemoresistance.2021BiomoleculesFree full text
  28. DEPDC1 upregulation promotes cell proliferation and predicts poor prognosis in patients with gastric cancer.2021Cancer biomarkers : section A of Disease markersFree full text
  29. HIF1A-AS2 Promotes the Proliferation and Metastasis of Gastric Cancer Cells Through miR-429/PD-L1 Axis.2021Digestive diseases and sciences
  30. Diagnostic value of multi-slice spiral CT (MSCT) combined with digestive tract angiography in gastric fundus cardia carcinoma.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  31. LINC01232 Promotes Gastric Cancer Proliferation through Interacting with EZH2 to Inhibit the Transcription of KLF2.2021Journal of microbiology and biotechnologyFree full text
  32. HOXB13 promotes gastric cancer cell migration and invasion via IGF-1R upregulation and subsequent activation of PI3K/AKT/mTOR signaling pathway.2021Life sciences
  33. Centromere Protein I (CENP-I) Is Upregulated in Gastric Cancer, Predicts Poor Prognosis, and Promotes Tumor Cell Proliferation and Migration.2021Technology in cancer research & treatmentFree full text
All its trials on ClinicalTrials.gov, any status12
  1. TEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)RecruitingNCT07714980Study siteN/AStart 2026-07
  2. TEAS for Gastrectomy RecoveryRecruitingNCT07898293Study siteN/AStart 2024-10
  3. First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)RecruitingNCT06730373Study sitePhase 2Start 2024-10
  4. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  5. Postoperative Adjuvant Therapy for Stage II-III Gastric CancerActive, not recruitingNCT06609759Study siteStart 2024-01
  6. Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric CancerActive, not recruitingNCT06693128Study sitePhase 2Start 2024-11
  7. Minimal Residual Disease-guided Adjuvant Therapy for Gastric CancerActive, not recruitingNCT06157216Study siteN/AStart 2023-10
  8. First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric CancerActive, not recruitingNCT05586061Study sitePhase 2Start 2023-02
  9. Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior ImmunotherapyActive, not recruitingNCT05585580Study sitePhase 2Start 2023-03
  10. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  11. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  12. Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerActive, not recruitingNCT04208347Study sitePhase 2/Phase 3Start 2019-12

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 47 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
47
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 101020212022: 4420222023: 6620232024: 121220242025: 13132025

2 hospitals in Yantai for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07815223

    Age 18 years to 75 years (registered criteria)

    Led by Yantai Yuhuangding HospitalYantai

  2. Recruiting
    A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06203210

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Shenyang, Tianjin, Urumqi, Wuhan, Xiangyang, Yantai, Zhengzhou

  3. Recruiting
    A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2022-11
    Posted
    Registry
    NCT05498428

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Harbin, Shanghai, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai

  4. Recruiting
    Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Posted
    Registry
    NCT04930432

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 56 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  5. Not yet recruiting
    A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer
    Phase
    Phase 4
    Started
    2026-05
    Posted
    Registry
    NCT07485920

    Age 18 years to Not stated (registered criteria)

    Led by Affiliated Hospital of Qingdao University; 1 listed hospital as study siteQingdao, Yantai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiation oncologyMedical oncologyPathology / laboratory medicineENT / head & neck surgery
Papers it led47
  1. Deep learning-based classification of lung adenocarcinoma subtypes in histopathological images using DS-EffNet.2026Human pathology
  2. Clinical Characteristics and Diagnostic-Therapeutic Analysis of Pulmonary Benign Metastasizing Leiomyoma: A 10-Case Retrospective Study and Systematic Review.2026The American surgeon
  3. Single-Port Thoracoscopic Surgery via Areola Approach for Lung Cancer: Feasibility, Safety, and Initial Experience With a Novel Technique.2025ANZ journal of surgery
  4. Kartagener Syndrome Complicated by Middle and Lower Lobar Mucinous Adenocarcinoma in the Left Lung.2025Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of AsiaFree full text
  5. Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in China.2025BMJ openRCTFree full text
  6. Clinical significance and biological function of PRKCQ-AS1/miR-582-3p expression in LUAD.2025HereditasFree full text
  7. Four-gene Prognostic Signature and Risk of Brain Metastasis of Lung Adenocarcinoma.2025Molecular carcinogenesisFree full text
  8. Non-small cell lung cancer subtype classification based on cross-scale multi-instance learning.2025Scientific reportsFree full text
  9. Advanced lung cancer inflammation index is associated with mortality in critically ill patients with non-traumatic cerebral hemorrhage.2025Scientific reportsFree full text
  10. Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China.2025Scientific reportsFree full text
  11. The effect of oral nutritional supplementation combined with probiotics on the liver function and intestinal microflora in lung cancer chemotherapy patients through the gut-liver axis.2025Scientific reportsRCTFree full text
  12. Anlotinib as Maintenance Therapy After First-Line Chemotherapy Combined with Consolidation Radiation for Extensive-Stage Small Cell Lung Cancer.2025Technology in cancer research & treatmentFree full text
  13. Effects of magnesium concentration on the regulation of nutrition and inflammation in nutritional support for cancer patients.2025The oncologistFree full text
  14. One-Stage Bilateral Pulmonary Nodule Resection via Unilateral Thoracic Cavity Access: A Single-Center Experience of 12 Cases.2025Thoracic cancerFree full text
  15. IMUP promotes fatty acid metabolism and lung cancer progression by regulating TGF-β/SMAD3 signaling pathway.2025Tissue & cell
  16. Surgery of enlarging lesions after stereotactic radiosurgery for brain metastases in patients with non-small cell lung cancer with oncogenic driver mutations frequently reveals radiation necrosis: case series and review.2024APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  17. Renal Metastasis Arising From a Pulmonary Adenoid Cystic Carcinoma: A Rare Case Report and Literature Review.2024American journal of men's healthFree full text
  18. Sex-based immune microenvironmental feature heterogeneity in response to PD-1 blockade in combination with chemotherapy for patients with untreated advanced non-small-cell lung cancer.2024Cancer medicineFree full text
  19. Obese Mouse Fat Cell-derived Extracellular Vesicles Transport miR-99a-5p to Mitigate the Proliferation and Migration of Non-small Cell Lung Cancer Cells.2024Combinatorial chemistry & high throughput screening
  20. Inhaled delivery of cetuximab-conjugated immunoliposomes loaded with afatinib: A promising strategy for enhanced non-small cell lung cancer treatment.2024Drug delivery and translational research
  21. Incidence of thromboembolic events in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.2024Journal of cancer research and therapeutics
  22. Prognostic significance of Pleural Fluid triglyceride levels based on a low-Fat Diet Management Strategy in patients with Chylothorax following pulmonary resection.2024Journal of cardiothoracic surgeryFree full text
  23. S-(N,N-diethyldithiocarbamoyl)-N-acetyl-l-cysteine for the treatment of non-small cell lung cancer through regulating NF-κB signalling pathway without neurotoxicity.2024Journal of drug targeting
  24. A cisplatin and disulphiram co-loaded inclusion complex overcomes drug resistance by inhibiting cancer cell stemness in non-small cell lung cancer.2024Journal of drug targeting
  25. Prophylactic Cranial Irradiation in Limited-Stage Small Cell Lung Cancer: A Meta-Analysis.2024Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  26. A disulfiram derivative against lung cancer via the Notch signaling pathway without neurotoxicity and hepatotoxicity.2024Naunyn-Schmiedeberg's archives of pharmacology
  27. Integrated single-cell and bulk RNA-Seq analysis enhances prognostic accuracy of PD-1/PD-L1 immunotherapy response in lung adenocarcinoma through necroptotic anoikis gene signatures.2024Scientific reportsFree full text
  28. Analysis and Validation of the Prognosis ability of the M7GRelated miRNAs in Lung Adenocarcinoma.2023Asian Pacific journal of cancer prevention : APJCPFree full text
  29. Tumor to liver maximum standardized uptake value ratio of FDG-PET/CT parameters predicts tumor treatment response and survival of stage III non-small cell lung cancer.2023BMC medical imagingFree full text
  30. The efficacy and safety of immune checkpoint inhibitors for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy: A systematic review and network meta-analysis.2023Cancer medicineFree full text
  31. Tumour-pleura relationship on CT is a risk factor for occult lymph node metastasis in peripheral clinical stage IA solid adenocarcinoma.2023European radiology
  32. Clinical characteristics and establishment of a 2-year-OS predictive model of EGFR mutation-positive patients with pleural invasion of lung adenocarcinoma.2023MedicineFree full text
  33. m6A methylation reader IGF2BP2 activates endothelial cells to promote angiogenesis and metastasis of lung adenocarcinoma.2023Molecular cancerFree full text
  34. Development of six immune-related lncRNA signature prognostic model for smoking-positive lung adenocarcinoma.2022Journal of clinical laboratory analysisFree full text
  35. Mechanism of mPEGS and FGF2 in miR-574-5p regulating pemetrexed resistance of lung adenocarcinoma in nude mice.2022Minerva medica
  36. Effect and mechanism of mir-574-5p regulating mpegs on drug resistance of pC9/h1993 cells.2022Panminerva medica
  37. The Perspectives and Lived Experience of Postoperative Patients with Lung Cancer Participating in a Home-Based Exercise Intervention.2022Seminars in oncology nursing
  38. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.2021BMC cancerFree full text
  39. Pinocembrin suppresses proliferation and enhances apoptosis in lung cancer cells in vitro by restraining autophagy.2021BioengineeredFree full text
  40. CircPRKCI regulates proliferation, migration and cycle of lung adenocarcinoma cells by targeting miR-219a-5p-regulated CAMK1D.2021European review for medical and pharmacological sciences
  41. Long non-coding RNA CCAT1 promotes non-small cell lung cancer progression by regulating the miR-216a-5p/RAP2B axis.2021Experimental biology and medicine (Maywood, N.J.)Free full text
  42. TWIST2 inhibits EMT and induces oxidative stress in lung cancer cells by regulating the FGF21-mediated AMPK/mTOR pathway.2021Experimental cell research
  43. Dosimetric Factors and Radiomics Features Within Different Regions of Interest in Planning CT Images for Improving the Prediction of Radiation Pneumonitis.2021International journal of radiation oncology, biology, physics
  44. CLK2 promotes occurrence and development of non-small cell lung cancer.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  45. FGF21 promotes non-small cell lung cancer progression by SIRT1/PI3K/AKT signaling.2021Life sciences
  46. Euphorbia angustifolia lactone B inhibits A549 proliferation and induces apoptosis.2021Pakistan journal of pharmaceutical sciences
  47. Pathological cytomorphologic features and the percentage of ALK FISH-positive cells predict pulmonary adenocarcinoma prognosis: a prospective cohort study.2021World journal of surgical oncologyFree full text
Chinese-language papers (not in the count)2
  1. [Pulmonary myopericytoma: report of a case].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [A case report of alveolar adenoma].2025Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
All its trials on ClinicalTrials.gov, any status22
  1. A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLCRecruitingNCT07815223Lead sponsorPhase 2Start 2025-11
  2. A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung CancerNot yet recruitingNCT07485920Study sitePhase 4Start 2026-05
  3. A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerRecruitingNCT06203210Study sitePhase 3Start 2024-05
  4. A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerRecruitingNCT05498428Study sitePhase 2Start 2022-11
  5. Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid TumorsRecruitingNCT04930432Study sitePhase 1/Phase 2Start 2021-09
  6. A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05488314Study sitePhase 1/Phase 2Start 2022-12
  7. A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)Active, not recruitingNCT05668988Study sitePhase 3Start 2022-12
  8. Study of KN046 in Subjects With Advanced Non-Small Cell Lung CancerCompletedNCT05420220Study sitePhase 2Start 2022-07
  9. A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05388669Study sitePhase 3Start 2022-08
  10. Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT05195632Study sitePhase 2Start 2022-06
  11. Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung CancerCompletedNCT04952597Study sitePhase 2Start 2021-07
  12. A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib FailureActive, not recruitingNCT04988295Study sitePhase 3Start 2021-11
  13. A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung CancerTerminatedNCT04746924Study sitePhase 3Start 2021-05
  14. A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 InsertionsActive, not recruitingNCT04538664Study sitePhase 3Start 2020-10
  15. A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT04487080Study sitePhase 3Start 2020-09
  16. Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung CancerCompletedNCT04005716Study sitePhase 3Start 2019-07
  17. A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung CancerStatus unknownNCT04641754Study sitePhase 2Start 2019-03
  18. Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung CancerStatus unknownNCT04102982Study sitePhase 2Start 2019-11
  19. Microwave Ablation in Ground Glass NodulesStatus unknownNCT03490890Study sitePhase 2Start 2018-05
  20. Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLCCompletedNCT02504489Study sitePhase 3Start 2015-12
  21. Individualized Adaptive Radiotherapy Based on PET/CT and IMRT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT02790190Study sitePhase 3Start 2015-05
  22. Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLCStatus unknownNCT02455843Study sitePhase 3Start 2015-05

Run the PubMed searchClinicalTrials.gov

Cancer

Pancreatic cancer

胰腺癌

Led 7 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 2220222023: 1120232024: 0020242025: 002025

1 hospital in Yantai for pancreatic cancer192 hospitals in China for pancreatic cancer

No open trial on pancreatic cancer lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatologyRadiology / nuclear medicineMedical oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 45 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
45
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 9920212022: 3320222023: 101020232024: 131320242025: 992025

1 hospital in Yantai for breast cancer219 hospitals in China for breast cancer

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07054242

    Age 18 years to 75 years (registered criteria)

    Led by Yantai Yuhuangding HospitalYantai

  2. Recruiting
    Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
    Phase
    Not given
    Started
    2026-05
    Posted
    Registry
    NCT06993506

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMS; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Hefei, Shanghai, Shijiazhuang, Wuhan, Xiamen, Yantai, Zhengzhou

  3. Recruiting
    A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07043725

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 52 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Harbin, Hefei, Hengyang, Jinan, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Xinxiang, Yantai, Zhengzhou

  4. Recruiting
    A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT07673029

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 51 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Meizhou, Nanchang, Nanning, Qingdao, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xi'an, Xinxiang, Xuzhou, Yantai, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineMedical oncologyPathology / laboratory medicineRadiation oncology
Papers it led45
  1. Prediction of non-sentinel lymph node metastasis using the clinical features of thrombin time under the status of 1-2 positive sentinel lymph node of breast cancer.2026Future oncology (London, England)Free full text
  2. Exosome Platform with Three-in-One Functionality of mRNA Therapy, Immune Checkpoint Blockade, and Mild Photothermal Therapy for the Treatment of Triple-Negative Breast Cancer.2025ACS applied materials & interfaces
  3. Predicting axillary lymph node metastasis in breast cancer patients using CNN-GCN on DCE-MRI: a multicenter study.2025BMC medical imagingFree full text
  4. Piezo1-mediated cellular apoptosis in breast cancer cells triggered by ultrasound and microbubbles.2025Cellular and molecular biology (Noisy-le-Grand, France)
  5. Anlotinib or Bevacizumab Combined with Taxane/Capecitabine for the Second-Line or Subsequent Treatment of HER-2 Negative Metastatic Breast Cancer: A Retrospective Cohort Study.2025Drug design, development and therapyFree full text
  6. Comparative Analysis of Clinical Efficacy and Safety of Pyrotinib Plus Capecitabine versus Trastuzumab Emtansine (T-DM1) as Second-Line Treatment for HER2-Positive Advanced Breast Cancer: A Retrospective Study.2025Drug design, development and therapyFree full text
  7. Development and multicenter external validation of an intratumoral and peritumoral ultrasound-based radiomics model for preoperative prediction of HER2 status in IHC 2 + breast cancer.2025European journal of medical researchFree full text
  8. Development and Validation of a Deep Learning System to Differentiate HER2-Zero, HER2-Low, and HER2-Positive Breast Cancer Based on Dynamic Contrast-Enhanced MRI.2025Journal of magnetic resonance imaging : JMRI
  9. Application of TRPS1 in ER-negative or low expression distant metastatic breast carcinoma.2025Pathology oncology research : PORFree full text
  10. Cyclophilin J inhibited oxidative stress and apoptosis in triple-negative breast cancer cell through activating the PI3K/Akt signaling pathway.2025Toxicology and applied pharmacology
  11. Develop and Validate a Nomogram Combining Contrast-Enhanced Spectral Mammography Deep Learning with Clinical-Pathological Features to Predict Neoadjuvant Chemotherapy Response in Patients with ER-Positive/HER2-Negative Breast Cancer.2024Academic radiology
  12. FAM110A could serve as a prognostic biomarker for patients with breast cancer: A comprehensive analysis by integrating bulk and single-cell sequencing.2024Asian journal of surgery
  13. Neuroendocrine Neoplasms of the Breast: Current Insights and Future Directions.2024Cancer reports (Hoboken, N.J.)Free full text
  14. A Case Report of Invasive Lobular Carcinoma of Breast with Multiple Gastrointestinal and Cutaneous Metastases.2024Current medical imaging
  15. Intracranial Efficacy of Pyrotinib and Capecitabine Combination Therapy in HER2-Positive Breast Cancer with Brain Metastases.2024Drug design, development and therapyFree full text
  16. Multiregional dynamic contrast-enhanced MRI-based integrated system for predicting pathological complete response of axillary lymph node to neoadjuvant chemotherapy in breast cancer: multicentre study.2024EBioMedicineFree full text
  17. Role of contrast-enhanced mammography in the preoperative detection of ductal carcinoma in situ of the breasts: a comparison with low-energy image and magnetic resonance imaging.2024European radiology
  18. Extrachromosomal circular DNA landscape of breast cancer with lymph node metastasis.2024International journal of cancer
  19. Artificial intelligence-based classification of breast lesion from contrast enhanced mammography: a multicenter study.2024International journal of surgery (London, England)Free full text
  20. Multitask Deep Learning-Based Whole-Process System for Automatic Diagnosis of Breast Lesions and Axillary Lymph Node Metastasis Discrimination from Dynamic Contrast-Enhanced-MRI: A Multicenter Study.2024Journal of magnetic resonance imaging : JMRI
  21. Nuclei detection in breast histopathology images with iterative correction.2024Medical & biological engineering & computing
  22. Low-intensity pulsed ultrasound combined with microbubble mediated JNK/c-Jun pathway to reverse multidrug resistance in triple-negative breast cancer.2024Scientific reportsFree full text
  23. Mammographically detected breast clustered microcalcifications localized by chest thin-section computed tomography.2024World journal of surgical oncologyFree full text
  24. Intra- and Peritumoral Radiomics of Contrast-Enhanced Mammography Predicts Axillary Lymph Node Metastasis in Patients With Breast Cancer: A Multicenter Study.2023Academic radiology
  25. Attention-based deep learning for breast lesions classification on contrast enhanced spectral mammography: a multicentre study.2023British journal of cancerFree full text
  26. Homologous recombination deficiency prediction using low-pass whole genome sequencing in breast cancer.2023Cancer genetics
  27. Landscape of NcRNAs involved in drug resistance of breast cancer.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of MexicoFree full text
  28. Prognostic value of left ventricular global longitudinal strain on speckle echocardiography for predicting chemotherapy-induced cardiotoxicity in breast cancer patients: A systematic review and meta-analysis.2023Echocardiography (Mount Kisco, N.Y.)
  29. Single nucleotide polymorphisms associated with female breast cancer susceptibility in Chinese population.2023Gene
  30. Radiomics of contrast-enhanced spectral mammography for prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer.2023Journal of X-ray science and technologyFree full text
  31. Attention-based Deep Learning for the Preoperative Differentiation of Axillary Lymph Node Metastasis in Breast Cancer on DCE-MRI.2023Journal of magnetic resonance imaging : JMRI
  32. Qualitative assessments of density and background parenchymal enhancement on contrast-enhanced spectral mammography associated with breast cancer risk in high-risk women.2023The British journal of radiologyFree full text
  33. Intratumoral and peritumoral radiomics for preoperatively predicting the axillary non-sentinel lymph node metastasis in breast cancer on the basis of contrast-enhanced mammography: a multicenter study.2023The British journal of radiologyFree full text
  34. miR-146a Enhances the Sensitivity of Breast Cancer Cells to Paclitaxel by Downregulating IRAK1.2022Cancer biotherapy & radiopharmaceuticals
  35. Intratumoral and peritumoral radiomics for preoperative prediction of neoadjuvant chemotherapy effect in breast cancer based on contrast-enhanced spectral mammography.2022European radiology
  36. Validation of absolutely quantitated Ki67 and cyclinD1 protein levels for prognosis of Luminal-like breast cancer patients.2022Journal of clinical laboratory analysisFree full text
  37. Identification of candidate biomarkers correlated with poor prognosis of breast cancer based on bioinformatics analysis.2021BioengineeredFree full text
  38. The correlation of 18F-FDG PET/CT metabolic parameters, clinicopathological factors, and prognosis in breast cancer.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  39. Radiomic analysis on magnetic resonance diffusion weighted image in distinguishing triple-negative breast cancer from other subtypes: a feasibility study.2021Clinical imaging
  40. Multiview multimodal network for breast cancer diagnosis in contrast-enhanced spectral mammography images.2021International journal of computer assisted radiology and surgery
  41. MIR31HG regulates the proliferation, migration and invasion of breast cancer by regulating the expression of POLDIP2.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  42. Preoperative prediction of histologic grade in invasive breast cancer by using contrast-enhanced spectral mammography-based radiomics.2021Journal of X-ray science and technology
  43. ELK1-induced up-regulation of KIF26B promotes cell cycle progression in breast cancer.2021Medical oncology (Northwood, London, England)
  44. Quantitative analysis of contrast enhanced spectral mammography grey value for early prediction of pathological response of breast cancer to neoadjuvant chemotherapy.2021Scientific reportsFree full text
  45. Mammography-based radiomics for predicting the risk of breast cancer recurrence: a multicenter study.2021The British journal of radiologyFree full text
Chinese-language papers (not in the count)1
  1. [The value of immunohistochemical expression of Ki-67 and CD34 in differentiating ductal carcinoma in situ from ductal carcinoma in situ-like invasive breast cancer].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status10
  1. A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)Not yet recruitingNCT07054242Lead sponsorPhase 2Start 2025-10
  2. Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast CancerStatus unknownNCT05800756Lead sponsorPhase 2Start 2022-08
  3. Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast CancerRecruitingNCT06993506Study siteStart 2026-05
  4. A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerRecruitingNCT07043725Study sitePhase 3Start 2025-09
  5. A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast CancerRecruitingNCT07673029Study sitePhase 3Start 2025-01
  6. A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast CancerActive, not recruitingNCT05346224Study sitePhase 3Start 2022-04
  7. GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast CancerCompletedNCT05054751Study sitePhase 3Start 2021-09
  8. A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver MetastasesStatus unknownNCT03500380Study sitePhase 2/Phase 3Start 2018-04
  9. Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast CancerCompletedNCT03084237Study sitePhase 3Start 2016-11
  10. Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In ChinaCompletedNCT01176916Study sitePhase 4Start 2011-02

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 2 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Yantai for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 3 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

8 hospitals in Yantai for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiation oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 2 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

3 hospitals in Yantai for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

4 hospitals in Yantai for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicineNeurology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 1 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Yantai for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesInfection & supportive care

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 1 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Yantai for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesTreatment regimensEBV & infection triggersLymphoma & cancer-related HLH
Departments in papersENT / head & neck surgery
Papers it led1
  1. Successful treatment of hemophagocytic syndrome in a patient with T cell lymphoma, EBV infection, and bone marrow necrosis: A case report.2022MedicineFree full text
Chinese-language papers (not in the count)1
  1. [Successful treatment of hemophagocytic syndrome caused by auricle infection: one case report].2021Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery

Run the PubMed searchClinicalTrials.gov

Blood disorders

Lymphoma

淋巴瘤

Led 12 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
12
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 3320232024: 2220242025: 332025

1 hospital in Yantai for lymphoma199 hospitals in China for lymphoma

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
    Phase
    Phase 1
    Started
    2025-04
    Posted
    Registry
    NCT06487624

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Hangzhou, Yantai

  2. Recruiting
    Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06829771

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Lanzhou, Luzhou, Quanzhou, Shanghai, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Zhengzhou

  3. Recruiting
    An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
    Phase
    Not given
    Started
    2025-09
    Posted
    Registry
    NCT07200375

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan, Nanchang, Ningbo, Shanghai, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai, Zhengzhou

  4. Recruiting
    Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06082102

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Dalian, Guangzhou, Hangzhou, Nanchang, Qingdao, Shanghai, Shenyang, Wuhan, Xi'an, Yantai, Zhengzhou

  5. Not yet recruiting
    Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
    Phase
    Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07187960

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chongqing, Guiyang, Haikou, Lanzhou, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Yantai, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicineRadiology / nuclear medicineENT / head & neck surgery
Papers it led12
  1. Diagnostic challenges and considerations in CD30-negative classical Hodgkin lymphoma from biopsy specimens.2026Annals of diagnostic pathology
  2. Genetic alterations and their prognostic impact in marginal zone lymphoma: a meta-analysis.2025Annals of hematologyFree full text
  3. Clinical analysis of lymphoma with malignant solid tumor simultaneously: a retrospective case series.2025Diagnostic pathologyFree full text
  4. Case Report: Epstein-Barr virus-positive follicular lymphoma with high PD-L1 expression.2025Frontiers in immunologyFree full text
  5. Clinical significance of Cyclin D1 by complete quantification detection in mantle cell lymphoma: positive indicator in prognosis.2024Diagnostic pathologyFree full text
  6. Nodal T follicular helper cell lymphoma with aberrant CD20 expression and monoclonal TCR, IG rearrangements secondary to Classical Hodgkin Lymphoma: a case report.2024Medical molecular morphology
  7. Advanced Ann Arbor stage and age over 60 years as prognostic predictors in patients with primary cervical lymphoma: a retrospective cohort study and systematic review.2023BMC cancerFree full text
  8. An extranodal Richter's syndrome presenting with cardiac diffuse large B-cell lymphoma: a case report.2023BMC cardiovascular disordersFree full text
  9. Differentiation between atypical sinonasal non-Hodgkin's lymphoma and inverted papilloma.2023Clinical radiology
  10. Targeting MYC and BCL2 by a natural compound for "double-hit" lymphoma.2022Hematological oncologyFree full text
  11. Successful treatment of hemophagocytic syndrome in a patient with T cell lymphoma, EBV infection, and bone marrow necrosis: A case report.2022MedicineFree full text
  12. Differentiating Glioblastoma from Primary Central Nervous System Lymphoma: The Value of Shaping and Nonenhancing Peritumoral Hyperintense Gyral Lesion on FLAIR Imaging.2021World neurosurgery
Chinese-language papers (not in the count)3
  1. [Diffuse large B cell lymphoma misdiagnosed as peritonsillar abscess: a case report].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  2. [Safety and the short-term efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with lymphoma].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  3. [Primary small lymphocytic lymphoma/chronic lymphocytic leukemia of the appendix with acute appendicitis as the first symptom: report of a case].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status7
  1. An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced TumorsRecruitingNCT06487624Study sitePhase 1Start 2025-04
  2. Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular LymphomaNot yet recruitingNCT07187960Study sitePhase 3Start 2025-11
  3. An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell LymphomaRecruitingNCT07200375Study siteStart 2025-09
  4. Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell LymphomaRecruitingNCT06829771Study sitePhase 1/Phase 2Start 2025-04
  5. Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone LymphomaRecruitingNCT06082102Study sitePhase 3Start 2023-12
  6. A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in ChinaActive, not recruitingNCT07226752Study sitePhase 3Start 2022-10
  7. Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT05479994Study sitePhase 2Start 2022-10

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Yantai for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 10 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.2%.

Papers led
10
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 4420242025: 332025

1 hospital in Yantai for coronary heart disease231 hospitals in China for coronary heart disease

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
    Phase
    Phase 4
    Started
    2025-11
    Posted
    Registry
    NCT07110415

    Age 40 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Dalian, Daqing, Guangzhou, Guiyang, Hangzhou, Harbin, Huzhou, Jinan, Lanzhou, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Xi'an, Yantai, Yinchuan, Zhangjiakou, Zhuhai

  2. Not yet recruiting
    Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
    Phase
    N/A
    Started
    2021-09
    Posted
    Registry
    NCT04995159

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 67 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Harbin, Hefei, Huai'an, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shantou, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Yinchuan, Zhanjiang, Zhengzhou, Zhongshan, Zhuhai, Zibo

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineNeurology
Papers it led10
  1. Tumour necrosis factor alpha-inducing protein 3 (TNFAIP3) can independently predict coronary heart disease (CHD).2025Acta cardiologica
  2. Combining echocardiography with carotid ultrasound parameters in predicting major adverse cardiovascular events among older individuals with coronary artery disease.2025PeerJFree full text
  3. Abnormal peripheral microcirculation by nailfold videocapillaroscopy reveals severity of atherosclerosis in coronary heart disease.2025Scientific reportsFree full text
  4. The diagnostic value of echocardiography combined with serum Hcy and PCSK9 in coronary heart disease.2024Biotechnology & genetic engineering reviews
  5. Screening significance of systemic immune-inflammation index (SII) and systemic inflammation response index (SIRI) in coronary heart disease of symptomatic youth.2024Immunity, inflammation and diseaseFree full text
  6. Unlocking Cardioprotective Potential of Gut Microbiome: Exploring Therapeutic Strategies.2024Journal of microbiology and biotechnologyFree full text
  7. Image testing based on biomedical drug loading in cardiovascular drug care simulation for coronary heart disease.2024Medical engineering & physics
  8. Decreased Regional Spontaneous Brain Activity and Cognitive Dysfunction in Patients with Coronary Heart Disease: a Resting-state Functional MRI Study.2023Academic radiology
  9. Association of early repolarization pattern and ventricular fibrillation in patients with vasospastic angina: A systematic review and meta-analysis.2022Clinical cardiologyFree full text
  10. Effect of Mobile Internet on Attitude and Self-Efficacy of Patients with Coronary Heart Disease Diagnosed by 12-Lead Holter ECG.2022Journal of healthcare engineeringFree full text
All its trials on ClinicalTrials.gov, any status3
  1. Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac DysfunctionRecruitingNCT07110415Study sitePhase 4Start 2025-11
  2. Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS SystemNot yet recruitingNCT04995159Study siteN/AStart 2021-09
  3. A Trial to Evaluate Efficacy of Heart-protecting Musk PillStatus unknownNCT01897805Study sitePhase 4Start 2011-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital heart disease

先天性心脏病

Led 2 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.08%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

1 hospital in Yantai for congenital heart disease207 hospitals in China for congenital heart disease

No open trial on congenital heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery
Papers it led2
  1. Kartagener Syndrome Complicated by Middle and Lower Lobar Mucinous Adenocarcinoma in the Left Lung.2025Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of AsiaFree full text
  2. Subdural Empyema Associated with Ventricular Septal Defect.2024Neurology India
Chinese-language papers (not in the count)1
  1. [A case of long QT syndrome with atypical clinical phenotype caused by KCNQ1-R555C missense mutation].2023Zhonghua xin xue guan bing za zhi

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led no English-language PubMed papers on anti-NMDA receptor encephalitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Yantai for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Yantai for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Yantai for Fabry disease80 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Yantai for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led 1 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Yantai for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Yantai for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status4
  1. A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune DiseasesNot yet recruitingNCT06774664Study sitePhase 1/Phase 2Start 2025-01
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  3. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09
  4. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Yantai for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Hereditary angioedema

遗传性血管性水肿

Led 1 of the 32 English-language PubMed papers on hereditary angioedema with an author in mainland China, 2021–2025: 3.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Yantai for hereditary angioedema30 hospitals in China for hereditary angioedema

No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersENT / head & neck surgery
Papers it led1
  1. Hereditary angioedema-induced laryngeal edema: A diagnostic and therapeutic race against time.2025The American journal of emergency medicine
All its trials on ClinicalTrials.gov, any status2
  1. A Phase 2 in Adult Subjects With Hereditary AngioedemaActive, not recruitingNCT06846398Study sitePhase 2Start 2025-02
  2. A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)CompletedNCT05460325Study sitePhase 3Start 2022-06

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

烟台毓璜顶医院

Yantai Yuhuangding Hospital

烟台

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Affiliated Yantai Yuhuangding Hospital of Qingdao University; Yantai Yuhuangding Hospital Affiliated to Qingdao University; Yuhuangding Hospital; Yuhuangding Hospital of Yantai; Affiliated Yantai Yuhuangding Hospital; Yuhuangding Hospital Affiliated to Qingdao University; Yantai Yuhuangding Hospital of Qingdao University; Yantai Yuhuangding Hospital Affilliated to Qingdao University

Suggest a correctionDownload the data